Oncology

For patients with NRG1 fusion–positive cancers, zenocutuzumab represents a promising novel targeted therapeutic option.

A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.

Look back at some of the important news and notes from last week you might have missed in the world of oncology from the FDA and the journal ONCOLOGY®.

During an After Hours segment of Medical World News®, Inga Lennes, MD, MBA, MPH, spoke about her passion for healthy cooking and how it helps her unwind after a busy week of treating patients.

A presentation at the recent 46th Annual Oncology Nursing Society’s Annual Meeting focused on ethical dilemmas facing oncology nurses and how clinicians are managing them.

An industry through leader recaps current challenges to traditional reimbursement models for Medical Economics®.

CancerNetwork® sat down with Health and Wellness expert Sonia Jhas to discuss best practices for staying active on a busy, demanding schedule.

The 2020 Trending Now in Cancer report highlighted a shift in oncology care resulting from the COVID-19 pandemic.

Look back at some of the important news and notes from last week you might have missed in the world of oncology. The FDA granted priority review to zanubrutinib, while 2 features from the journal ONCOLOGY® published on belantamab mafodotin and renal cell carcinoma, respectively, were popular with readers.

Phase 3 data supported the FDA in their decision to grant priority review to a new drug application for maribavir as therapy for certain patients with cytomegalovirus following transplant.

Based on outcomes from a study involving patients with cancer, Medicaid may benefit from expansion in certain areas where eligibility limits hinder adequate coverage.

Seventeen years of data indicate that HPV-related cervical cancer incidence is declining, but other tumors related to the virus persist.

Recommendations published in JAMA are set to change colorectal cancer screening guidance for all individuals in the United States.

Look back at some of the important news and notes from last week you might have missed in the world of oncology, featuring 2 FDA breakthrough device designations and a manuscript from the journal ONCOLOGY® focusing on molecular testing practices in pancreatic adenocarcinoma.

During an After Hours segment of Medical World News®, Amy Comander, MD, spoke about her passion for marathon running and how it helps keep her inspired in her work as an oncologist.

In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the utility of next-generation sequencing in pancreatic ductal adenocarcinoma.

Look back at some of the important news and notes from last week in the world of oncology, featuring an FDA approval and a Journal ONCOLOGY® article on prostate cancer disease states.

During an After Hours segment of Medical World News®, Loren Winters, MSN, ANP-BC, OCN, spoke about her passion for health and wellness, expressed through yoga instruction and Ayurvedic health coaching.

CancerNetwork® spoke with Sanju Sinha of the National Cancer Institute about the resulting data from his research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

CancerNetwork® sat down with Hans P.A. Van Dongen, PhD, Shobhan Gaddameedhi, PhD, and Jason McDermott, PhD, to discuss their research into how circadian disruptions may lead to changes in cancer-related genes.

Look back at some of the important news and notes from last week in the world of oncology, featuring articles from live events, the latest issue of the Journal ONCOLOGY®, and an episode of “Oncology Peer Review On-The-Go.”

CancerNetwork® spoke with Neelam and Sanju Sinha of the National Cancer Institute about their research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

CancerNetwork® sat down with Health and Wellness expert Sonia Jhas to discuss best practices for avoiding unhealthy eating habits on a demanding schedule.

Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as therapy for patients with RET-altered advanced solid tumors who were treated on the LIBRETTO-001 trial.

Look back at some of the important news and notes from last week in the world of oncology, featuring articles from the latest issue of the Journal ONCOLOGY®.